NMPA Approves SKB575/HBM7575 for Treating Atopic Dermatitis in China Kelun-Biotech and Harbour BioMed celebrate NMPA approval for their innovatively designed SKB575/HBM7575, targeting atopic dermatitis.

NMPA Approves SKB575/HBM7575 for Treating Atopic Dermatitis in China #China #Chengdu #Kelun-Biotech #Harbour_BioMed #SKB575